Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

h and development 906 (2) - - 904 Other expense/(income), net 134 - - - 134 Special and acquisition-related charges 94 - (94) - - Equity income (493) - - 64 (429) ----- - - -- ----- Income before income taxes 502 357 94 (64) 889 Income tax expense/(benefit) 40 (73) (7) - 120 -- ---- --- - --- Net income $462 $284 $87 $(64) $769 ---- ---- === ---- ---- Preferred stock dividends 38 - - - 38 -- - - - -- Net income available to common shareholders $424 $284 $87 $(64) $731 ==== ==== === ==== ==== Diluted earnings per common share $0.26 $0.45 ===== ===== Average shares outstanding common and participating - diluted 1,632 1,632 (1) "As Reconciled" to exclude purchase accounting adjustments, special and acquisition-related items and other specified items.


    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... San Mateo, CA (PRWEB) July 14, 2014 ... groundbreaking CONNECT patient registry platform, announced that ... Becker muscular dystrophies; the Phelan-McDermid Syndrome International ... primary Nephrotic Syndrome—have been awarded contracts by ... part of the creation of a new ...
(Date:7/13/2014)... -- The discovery 30 years ago of soccer-ball-shaped carbon ... nanotechnology research. Now, there appears to be a new ... Shanxi University and Tsinghua University in China have shown ... hollow molecular cage similar to a carbon buckyball. It,s ... only a matter of speculationdoes indeed exist. , "This ...
(Date:7/13/2014)... 2014 Deep Research Report on Global and China ... on the current state of the Nano Silver industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
Breaking Biology Technology:PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3
... - Appointment Enhances Algeta,s Commercial Capabilities ... Cancer , Algeta ASA ... Kay has been appointed as President and Chief,Executive Officer and ... Thomas,Ramdahl will continue as Executive Vice President and Chief Technology,Officer ...
... TUSTIN, Calif., Dec. 11 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... its Board of Directors, unexpectedly passed away on Wednesday. Dr. ... chairman since 2005. At the time of his death, Dr. ... , , "The sudden ...
... Alimera Sciences Inc., a privately held,biopharmaceutical company ... prescription ophthalmic pharmaceuticals, today reported,that enrollment has begun ... and efficacy,of Iluvien(TM) in patients with bilateral geographic ... The pilot ...
Cached Biology Technology:Algeta Appoints Andrew Kay as President and Chief Executive Officer 2Algeta Appoints Andrew Kay as President and Chief Executive Officer 3Algeta Appoints Andrew Kay as President and Chief Executive Officer 4Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/11/2014)... of all vertebrates, information is transmitted through synapses, ... signal to be passed from one brain cell ... abundant type of synapse, can be either excitatory ... memory, perception and cognition, and the balance between ... For instance, every time we learn something, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... shellfish, snails and other animals from the Pacific Ocean ... was interrupted by cooling conditions three million years ago, ... of California, Davis, and Peter Roopnarine at the California ... ice-free Arctic Ocean by 2050. That will restore conditions ...
... Pharmacy researchers have discovered a marine compound off the ... in laboratory tests, a finding they hope will fuel ... disease. The UF-patented compound, largazole, is derived from ... results from early studies today (Aug. 7) at an ...
... The University of Houston department of health and human performance ... a study promoting healthy dietary habits and physical activity. ... of Second Life (SL). , ... is part of the UH Texas Obesity Research Center,s (TORC) ...
Cached Biology News:Pacific shellfish ready to invade Atlantic 2Researchers find cancer-inhibiting compound under the sea 2Researchers find cancer-inhibiting compound under the sea 3TORC at UH turns to virtual world of Second Life for new study 2
XEDAR Antibody...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
...
Biology Products: